Zentalis Pharmaceuticals, Inc.ZNTL

Zentalis Pharmaceuticals, Inc. Segments Disclosure

10-KFiled Mar 26, 20262 min read
Segment Reporting and Disaggregation of Relevant Expense Captions
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The determination of a single business segment is consistent with the consolidated financial information periodically reviewed by the Chief Executive Officer as chief operation decision maker ("CODM") in assessing segment performance and deciding how to allocate resources.

The CODM uses net income or loss to monitor budgets, forecasts and expected cash flows in assessing segment performance and in deciding how to allocate resources. The measure of segment assets is reported on the consolidated balance sheets as total assets.
The following table presents information about reported significant segment expenses and net loss (in thousands):
 
Year ended December 31,
202520242023
Revenues
$— $67,425 $— 
Less:
Research and development (1):
Azenosertib external development costs
48,102 75,837 67,019 
Unallocated research and development expenses and discontinued programs
59,193 91,931 122,571 
Total Research and development
107,295 167,768 189,590 
General and administrative
37,717 87,115 64,351 
Other (2)
(7,952)$(21,591)38,364 
Net loss
(137,060)(165,867)(292,305)
Adjustments for cash used in operations:
Non-Cash expenses
20,935 11,547 78,619 
Changes in working capital
(9,122)(16,540)5,864 
Cash used in operations:
$(125,247)$(170,860)$(207,822)

(1) The Company tracks external development costs by product candidate or development program, but does not allocate personnel costs, general license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses and discontinued programs.
(2) Other consists of investment and other income, net, restructuring, goodwill impairment charges, Zentera in-process research and development, Income tax expense (benefit), and loss on equity method investment.

Historical Timeline

Fiscal YearFiled
2025Mar 26, 2026Showing above
2024Mar 26, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ECommitmentsNew StandardsPay vs Performance